Acadia Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
19.95
+0.06 (0.30%)
Oct 2, 2026, 4:00 PM EDT - Market closed
Acadia Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,139 | 1,072 | 957.8 | 726.44 | 517.24 | 484.15 | |
Revenue Growth | 11.75% | 11.87% | 31.85% | 40.45% | 6.83% | 9.60% |
Cost of Revenue | 431.99 | 417.8 | 385.09 | 393.26 | 371.74 | 258.56 |
Gross Profit | 706.66 | 653.71 | 572.71 | 333.18 | 145.49 | 225.59 |
Selling, General & Admin | 620.29 | 548.89 | 488.43 | 406.56 | 369.09 | 396.03 |
Operating Expenses | 620.29 | 548.89 | 488.43 | 406.56 | 369.09 | 396.03 |
Operating Income | 86.37 | 104.81 | 84.28 | -73.38 | -223.6 | -170.44 |
Interest & Investment Income | 32.62 | 31.72 | 25.46 | 17.23 | 6.61 | 0.59 |
Other Non Operating Income (Expenses) | 2.38 | 2.37 | 1.82 | - | - | - |
EBT Excluding Unusual Items | 121.37 | 138.9 | 111.56 | -56.15 | -216.99 | -169.85 |
Gain (Loss) on Sale of Investments | - | - | - | 5.11 | 3.54 | 2.33 |
Gain (Loss) on Sale of Assets | - | - | 146.52 | - | - | - |
Pretax Income | 121.37 | 138.9 | 258.08 | -51.04 | -213.44 | -167.52 |
Income Tax Expense | -259.12 | -252.1 | 31.62 | 10.25 | 2.53 | 0.35 |
Net Income | 380.48 | 391 | 226.45 | -61.29 | -215.98 | -167.87 |
Net Income to Common | 380.48 | 391 | 226.45 | -61.29 | -215.98 | -167.87 |
Net Income Growth | 71.27% | 72.66% | - | - | - | - |
Shares Outstanding (Basic) | 170 | 168 | 166 | 164 | 162 | 160 |
Shares Outstanding (Diluted) | 172 | 170 | 166 | 164 | 162 | 160 |
Shares Change | 2.98% | 2.14% | 1.55% | 1.32% | 0.74% | 2.01% |
EPS (Basic) | 2.24 | 2.32 | 1.37 | -0.37 | -1.34 | -1.05 |
EPS (Diluted) | 2.21 | 2.30 | 1.36 | -0.37 | -1.34 | -1.05 |
EPS Growth | 66.40% | 69.12% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 145.63 | 105.15 | 157.2 | 16.65 | -114.04 | -126.78 |
Free Cash Flow Per Share | 0.84 | 0.62 | 0.94 | 0.10 | -0.70 | -0.79 |
Gross Margin | 62.06% | 61.01% | 59.79% | 45.87% | 28.13% | 46.59% |
Operating Margin | 7.58% | 9.78% | 8.80% | -10.10% | -43.23% | -35.20% |
Profit Margin | 33.42% | 36.49% | 23.64% | -8.44% | -41.76% | -34.67% |
Free Cash Flow Margin | 12.79% | 9.81% | 16.41% | 2.29% | -22.05% | -26.19% |
EBITDA | 98.39 | 116.57 | 100.16 | -67.83 | -221.57 | -167.1 |
EBITDA Margin | 8.64% | 10.88% | 10.46% | -9.34% | -42.84% | -34.51% |
D&A For EBITDA | 12.02 | 11.76 | 15.88 | 5.55 | 2.03 | 3.34 |
EBIT | 86.37 | 104.81 | 84.28 | -73.38 | -223.6 | -170.44 |
EBIT Margin | 7.58% | 9.78% | 8.80% | -10.10% | -43.23% | -35.20% |
Effective Tax Rate | - | - | 12.25% | - | - | - |
Revenue as Reported | 1,139 | 1,072 | 957.8 | 726.44 | 517.24 | 484.15 |
Advertising Expenses | - | 31.9 | 21.1 | 9.4 | 5.5 | 41.8 |